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Abstract
Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific 
or nonspecific binding to unintended membrane protein targets; however, distinguishing the 
binding of drugs to membrane proteins from that of detergents, lipids and cofactors is challenging. 
Here we use high-resolution mass spectrometry to study the effects of HIV protease inhibitors on 
the human zinc metalloprotease ZMPSTE24. This intramembrane protease plays a major role in 
converting prelamin A to mature lamin A. We monitored proteolysis of farnesylated prelamin A 
peptide by ZMPSTE24 and unexpectedly found retention of the C-terminal peptide product with 
the enzyme. We also resolved binding of zinc, lipids, and HIV protease inhibitors and showed that 
drug binding blocked prelamin A peptide cleavage and conferred stability to ZMPSTE24. Our 
results not only have relevance for the progeria-like side effects of certain HIV protease inhibitor 
drugs but also highlight new approaches for documenting off-target drug binding.
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Introduction
Intramembrane proteases such as rhomboids, presenilin, and signal peptide peptidase are 
intriguing because of their ability to cleave peptide bonds within the lipid bilayer (reviewed 
in1). Understanding the catalytic mechanism and substrate-binding properties of these 
proteases poses technical challenges because of the hydrophobicity of the proteases 
themselves as well as of their substrates. To study the function of intramembrane proteases, 
these proteins are extracted and purified in detergents to keep the protein in solution and in 
an active state. Mass spectrometry of membrane proteins offers a powerful means for 
studying the behaviour of these proteins, primarily because this approach offers the potential 
to deconvolute a subset of potential ligand-binding moieties2,3, including lipids, substrates, 
metal ions, and drugs. Simultaneous binding of these factors has not been demonstrated 
previously using mass spectrometry due to the limited resolution available in earlier 
experiments. To evaluate the capacity of mass spectrometry to monitor off-target binding of 
drugs and to uncover mechanistic implications of this binding, we have investigated the 
interaction between HIV protease inhibitors and the human integral membrane 
metalloprotease ZMPSTE24.
ZMPSTE24 is a recently characterised member of the intramembrane class of proteases 
whose catalytic site lies within the plane of the lipid bilayer1,4,5. The X-ray structure of 
human ZMPSTE24 was solved at 3.4 Å, revealing a seven transmembrane α-helical barrel 
structure surrounding a voluminous water-filled, intramembrane chamber, capped by a zinc 
metalloprotease domain6. The catalytic site, including the zinc ion, faces into the chamber. 
Analogous features were identified in the yeast orthologue Ste24p7. Remarkably, the 
intramembrane cavities in ZMPSTE24 and Ste24p are large enough to accommodate a 10-
kDa protein or ~1000 water molecules. Whether lipids might be housed within this chamber 
is not known. Human ZMPSTE24 is an endoplasmic reticulum/nuclear membrane protease 
that has dual functions in the maturation and processing of prelamin A to lamin A. First, 
ZMPSTE24 is capable of cleaving the last three residues (SIM) from prelamin A’s carboxyl-
terminal CaaX motif (where C is cysteine, a is generally an aliphatic amino acid, and X is 
any residue). This CaaX-cleavage step is also performed by another ER membrane protease, 
RCE18,9. In a second and unique function, ZMPSTE24 mediates the final step of lamin A 
biogenesis, clipping off the last 15 amino acid residues of prelamin A, including its C-
terminal farnesylcysteine10. This step releases mature lamin A, which is one of the principal 
protein components of the nuclear lamina.
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Defective ZMPSTE24-mediated processing of prelamin A causes progeroid syndromes with 
clinical phenotypes resembling those of physiologic aging, for example thin skin, partial 
lipodystrophy, osteoporosis, and atherosclerotic coronary disease. The classic premature 
aging disorder of children, Hutchinson-Gilford progeria syndrome, is caused by a splicing 
mutation that results in an internal deletion of 50 amino acids within the carboxyl terminus 
of prelamin A; this deletion eliminates the ZMPSTE24 cleavage site in prelamin A and 
thereby blocks eliminates the endoproteolytic cleavage step that would ordinarily release 
mature lamin A11. ZMPSTE24 null mutations that completely block ZMPSTE24 activity 
result in restrictive dermopathy, a severe neonatal progeroid disorder characterized by a 
complete blockade of lamin A biogenesis and a striking accumulation of farnesyl–prelamin 
A12. Partial loss-of-function ZMPSTE24 mutations that do not fully block lamin A 
biogenesis lead to a moderate accumulation of farnesyl–prelamin A and a less severe 
progeroid disorder called mandibuloacral dysplasia13–15.
Interestingly, several HIV protease inhibitors (e.g., lopinavir, ritonavir, amprenavir) but not 
others (e.g., darunavir) block ZMPSTE24 activity in cultured fibroblasts and lead to an 
impressive accumulation of farnesyl–prelamin A. Futhermore, biochemical studies showed 
these inhibitors blocked the enzymatic activity of purified yeast Ste24p16–18. These were 
surprising findings, as the HIV proteases are aspartyl proteases, whereas ZMPSTE24 and 
Ste24p are zinc metalloproteases with a distinct mechanism of catalysis. It is noteworthy that 
long-term therapy with certain HIV protease inhibitors, including lopinavir/ritonavir 
(Kaletra), has been associated with aging-like phenotypes similar to those in patients with 
progeroid syndromes (partial lipodystrophy, atherosclerotic disease, osteoporosis)16,19,20. 
Indeed, when human or mouse fibroblasts are incubated with therapeutic concentrations of 
lopinavir, the amount of prelamin A accumulation is nearly as great as that in fibroblasts 
from patients with debilitating progeroid disorders13,21. At this point, however, the extent to 
which the progeria-like side effects of HIV protease inhibitors can be attributed to 
ZMPSTE24 inhibition is controversial, in part because other drugs within in commonly 
prescribed antiretroviral drug cocktails may also contribute to the observed side effects22. 
Importantly, while the ability of some HIV- protease inhibitors to block prelamin A 
processing in cultured cells is well established16,17 until the present work there has been no 
direct evidence showing that HIV protease inhibitors bind to human ZMPSTE24 at the 
molecular level.
In this study, we develop and apply a high-resolution mass spectrometry approach23 adapted 
for membrane proteins24 to understand the capacity of human ZMPSTE24 to cleave 
prelamin A and to better characterize the metal-, lipid-, and drug-binding properties of the 
membrane protein. Our studies monitor the proteolytic processing of prelamin A and 
investigate whether the products of the cleavage reaction remain within ZMPSTE24’s 
intramembrane chamber. We also probe the ability of HIV protease inhibitors to bind to 
ZMPSTE24 and inhibit the processing of prelamin A. We show that some HIV protease 
inhibitors, but not others, bind ZMPSTE24, prevent the cleavage of prelamin A, and lead to 
increased stability of the enzyme, as judged by resistance to unfolding.
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Results
Mass spectra of ZMSTE24 reveal binding of zinc and phospholipids
ZMPSTE24 was expressed in Sf9 cells and purified in the detergent octyl glucose neopentyl 
glycol (OGNG) with cholesteryl hemisuccinate (CHS) as described6 ZMPSTE24 was 
introduced into the Q Exactive Orbitrap mass spectrometer under conditions optimised for 
the preservation of noncovalent interactions23,25 and adapted for transmission of membrane 
proteins24 (Fig. 1). The charge state series confirms the mass of the protein and reveals two 
additional charge state series corresponding to the association of lipids co-purifying with the 
enzyme. Expansion of the predominant charge state (16+) exposes the presence of a small 
population of apo ZMPSTE24 (with a mass difference of 62 Da, consistent with an absence 
of a zinc ion) (Fig. 1 inset). The catalytic Zn2+ ion is essential for binding and cleavage of 
prelamin A peptides and its presence in the majority of the ZMPSTE24 molecules implies 
that the Zn2+ coordination site is maintained.
The interaction of ZMPSTE24 with substrate peptides
We first used western blots of SDS-polyacrylamide gels to verify prelamin A accumulation 
in a human fibroblast cell line treated with either a protein farnesyltransferase inhibitor 
(ABT-100, 0.5 μM) or lopinavir (20 μM). The blots were incubated with a goat IgG against 
human lamin A/C or a monoclonal antibody against the C-terminus of prelamin A. These 
studies showed that the protein farnesyltransferase inhibitor caused an accumulation of 
nonfarnesylated prelamin A, whereas lopinavir led to an accumulation of farnesyl–prelamin 
A (Supplementary Fig. 1) and validate our previous findings16,17.
To investigate the interactions of the protein ZMPSTE24 with prelamin A at the molecular 
level, ZMPSTE24 in OGNG/CHS micelles was incubated with equimolar amounts of a 26-
mer farnesylated synthetic peptide corresponding to the C terminus of prelamin A 
(Supplementary Fig. 2). The synthetic peptide mimics the prelamin A substrate in 
mammalian cells, except that the synthetic peptide terminates with a farnesylcysteine rather 
than a farnesylcysteine methyl ester. Mass spectra were acquired before adding the synthetic 
peptide and at intervals for a period of 1 h (Fig. 2). After a 2-min incubation at room 
temperature, the mass spectrum shows two charge states series—assigned to the ZMPSTE24 
protein and the 26-mer prelamin A peptide bound to ZMPSTE24. Although partial collapse 
of the large intramembrane chamber in the gas phase cannot be ruled out, the survival of this 
large noncovalently bound ZMPSTE24 peptide at collision energies required to completely 
release the OGNG micelle implies that the sequestration within the chamber protects the 
peptide from dissociation.
After a 2-min incubation period of the peptide with ZMPSTE24, peaks were also observed 
that correspond to the binding of ZMPSTE24 to the proteolytically processed peptide 
product (i.e., a farnesylated 15-mer peptide released from the 26-mer peptide). Surprisingly, 
the wild-type ZMPSTE24 and the farnesylated 15-mer peptide product formed a stable 
complex, with the 15-mer peptide remaining bound to ZMPSTE24 for time periods ranging 
from 1 to 24 h. In a control experiment, we performed studies with a catalytically inactive 
mutant ZMPSTE24 protein (ZMPSTE24-E336A) and found no interaction between 
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ZMPSTE24-E336A and the prelamin A peptide without the C-terminus. It is also possible to 
follow ZMPSTE24-mediated cleavage of the prelamin A peptide by studying the release of 
low-molecular weight peptide products following activation in the gas phase. The full-length 
peptide substrate and its product peptide were assigned as triply- and doubly-charged species 
(m/z 1016 and 903, respectively), corresponding to masses of 3046 Da and 1806 Da, 
respectively (Supplementary Fig. 3). After ~12 min, the peak corresponding to substrate 
peptide had significantly diminished and there was no further increase in the intensity of the 
product at 60 min. We interpret these findings as showing complete endoproteolytic 
processing of the peptide and conclude that the cleavage reaction is nearly complete by ~12 
min.
To define the impact of protein farnesylation on protease activity, ZMPSTE24 was incubated 
with a 14-mer synthetic peptide spanning the second cleavage site for prelamin A 
(Supplementary Fig. 2). This nonfarnesylated peptide was incubated in an equimolar ratio 
with ZMPSTE24 at a concentration of 15 μM. Hydrolysis was monitored in real time as 
above, and a digested peptide fragment was detected at low intensity at m/z 525 after ~10 
min (Supplementary Fig. 4). Approximately 35% of the nonfarnesylated peptide was 
hydrolysed after 1 h. The slow product formation with the nonfarnesylated peptide stands in 
contrast to results with the farnesylated 26-mer peptide, where the endoproteolytic cleavage 
reaction was complete within ~15 min. Moreover, binding of the 10-mer cleavage product 
within the ZMPSTE24 chamber could not be detected in the mass spectrum at the 
concentrations tested (data not shown). Together, these observations confirm the importance 
of protein farnesylation for efficient prelamin A processing and for binding of the cleaved 
peptide within the ZMP cavity.
Drug binding to ZMPSTE24
To explore the binding of drugs to ZMPSTE24, we added lopinavir (15 μM) to form an 
equimolar solution of ZMPSTE24 in C8E4. Several adduct peaks were observed and 
resolved using the high-resolution Q Exactive Orbitrap mass spectrometer. Peaks were 
assigned to association with cholesterol hemisuccinate (CHS) (present in the purification 
buffer), OGNG, and lopinavir (Supplementary Fig. 5). At the very same drug concentrations 
and with the same experimental conditions, binding of amprenavir and ritonavir were 
observed, albeit in lower amounts (i.e., lower peak intensities for drug-bound states). 
Interestingly, the higher molecular mass of ritonavir made it possible to confirm binding to 
the apo form of ZMPSTE24 as well as to the Zn2+-bound enzyme. Another HIV protease 
inhibitor, darunavir, which shares some structural features with lopinavir and ritonavir, 
showed no binding to ZMPSTE24 at the same 15 μM concentration used for the other drugs. 
Our results establish an order of affinity (based on peak height and identical mass 
spectrometry procedures and identical solution concentrations) with lopinavir > ritonavir > 
amprenavir > darunavir.
In order to probe further the different binding affinities of ZMPSTE24 to the HIV protease 
inhibitors we performed a competitive drug-binding assay. Three inhibitors (lopinavir, 
ritonavir, darunavir) were mixed at equimolar concentrations (7 μM) and added to a solution 
of ZMPSTE24. Low concentrations of DMSO are required to retain solubility of these 
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drugs. The final concentration of each drug in the 1:1:1 solution was 7 μM. The resulting 
mass spectrum reveals peaks at low m/z consistent with the masses of each drug (Figure 3). 
At the high m/z region, binding to ZMPSTE24 of lopinavir and ritonavir, but not darunavir, 
is observed; in addition, adduct peaks were assigned to CHS and OGNG. Interestingly the 
intensities of the peaks assigned to ZMPSTE24–drug conjugates showed similar trends to 
the intensity profiles observed when the drugs were added separately to ZMPSTE24 
(Supplementary Fig. 5), with lopinavir forming a higher population of protein drug 
conjugate than ritonavir.
To obtain relative binding affinities of the HIV-PIs, we determined their solution phase 
dissociation constants with established mass spectrometry methods3,26. We varied the 
concentration of lopinavir and ritonavir in intervals of 2.5 μM from 4 μM to 20 μM (and 
used a fixed concertation of ZMPSTE24, 15 μM). The mass spectra clearly show an increase 
in drug binding to ZMPSTE24 with increasing concentrations of each HIV-PI 
(Supplementary Fig. 6). The solubility of the drugs limited the upper range of the 
concentrations that could be tested, but measurements at low μM concentrations were carried 
out in triplicate and were reproducible (Supplementary Fig. 7). The KD values obtained by 
this method were 25 ± 1.2 and 30 ± 1.3 μM for lopinavir and ritonavir, respectively.
ZMPSTE24 activity is blocked by HIV protease inhibitors
Having documented binding of HIV-PIs to ZMPSTE24, the next question was whether this 
binding affected the catalytic activity of ZMPSTE24 against the 26-mer prelamin A peptide 
(Fig. 2). After first establishing that ZMPSTE24 retains catalytic activity in the presence of 
the detergent used for drug-binding experiments (C8E4), we tested whether it is possible to 
form a ZMPSTE24–drug–prelamin A peptide ternary complex. In our initial studies, we 
added lopinavir to ZMPSTE24 before attempting to detect the ZMPSTE24–lopinavir–
peptide complex. However, after adding lopinavir to the enzyme, we could detect binding of 
lopinavir to ZMPSTE24, but we were unable to detect binding of the prelamin A peptide to 
ZMPSTE24. Moreover, the mass spectrum recorded at low m/z values indicated that the 
peptide remained intact and did not undergo cleavage. In contrast, when ZMPSTE24 was 
incubated in the presence of darunavir, we detected proteolysis of the prelamin A peptide at 
low m/z. This is direct confirmation that darunavir—in contrast to lopinavir—does not bind 
to ZMPSTE24 and block its activity.
Given that HIV-PIs such as lopinavir prevent the binding of prelamin A peptide and block 
the endoproteolytic cleavage reaction, they likely bind to the active site of the enzyme within 
ZMPSTE24’s large intramembrane chamber. We suspected that this binding event might 
confer stability to ZMPSTE24 and increase its resistance to protein unfolding in the gas 
phase. We used ion-mobility mass spectrometry (IM-MS)27–29, a technique that measures 
the rotational collision cross section, to compare the stability of ZMPSTE24–drug 
conjugates with the apo form. IM-MS has been used previously to assess the effects of lipid 
binding to membrane proteins30,31, and in these studies, the ligand-bound protein complex 
was compared with the apo protein in the same spectrum. Considering first the unfolding 
trajectory of the Zn-bound protein, we note that it transitions from a compact native-like 
state at low collision energies (~70 V, 11+ charge state) to a relatively long-lived 
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intermediate and an unfolded states with arrival times of 3.6 ms and 5.3 ms at 70 and 140 V, 
respectively (Supplementary Fig. 8). Selecting the ritonavir-bound protein ions and 
subjecting these to increasing collision energy altered the corresponding unfolding 
transitions. Notably, the onset of the intermediate state occurred at higher activation voltages 
for the ritonavir-bound state than for the Zn-bound protein (~80 V). Similarly, when 
lopinavir was added to ZMPSTE24 and the lopinavir-bound peak subjected to collisional 
activation, the transition to the intermediate state occurred at higher collision energies (~85 
V), consistent with stabilisation of the protein–drug conjugate and increased resistance to 
unfolding with respect to the zinc-bound form. We conclude that both ritonavir and lopinavir 
stabilise ZMPSTE24 and that the effect is greater for lopinavir, consistent with the more 
favourable KD value determined for lopinavir binding to the enzyme.
Discussion
In the current study, we showed the utility of novel mass spectrometry approaches to study 
the intramembrane metalloprotease ZMPSTE24. We monitored and resolved the binding of 
metal ions, lipids, drugs, and detergents, and investigated the processing of a farnesylated 
26-mer peptide prelamin A substrate. We examined the binding and cleavage of the peptide 
substrate, as well as the fate of the 15-mer farnesylated peptide cleavage product. That a 
population of the cleaved peptide can be retained within the intramembrane chamber of 
ZMPSTE24 for at least 24 h implies that there is a tight association between ZMPSTE24 
and the cleavage product. However, we cannot exclude the possibility that the cleaved 
farnesylated 15-mer peptide product is released from ZMPSTE24 in vivo in the presence of 
a lipid bilayer or is released in the presence of specific protein binding partners. In any case, 
our observation of persistent binding of the cleaved peptide to ZMPSTE24 in vitro is 
intriguing and indicates an unexpected stability of the peptide–ZMPSTE24 complex. We 
speculate that the sequestration of the peptide product within the ZMPSTE24 chamber could 
serve to protect the cell from toxic effects of the farnesylated peptide. Presumably, the 
peptide is eventually released from the intramembrane chamber into an ER luminal 
compartment for disposal.
It is widely assumed that protein farnesylation facilitates the association of prelamin A with 
nuclear membranes and assists in the delivery of mature lamin A to the nuclear lamina32, but 
recent studies suggest that this effect may be rather modest in vivo. Genetically modified 
mice that synthesize mature lamin A directly (bypassing prelamin A synthesis and prelamin 
A processing steps) have no obvious abnormality in the targeting of lamin A to the nuclear 
rim33. However, the fact that prelamin A farnesylation and prelamin A proteoltyic 
processing has been conserved during evolution strongly suggests that it must be 
functionally important. At this point, the “physiologic rationale” for prelamin A 
farnesylation is incompletely understood, but the current studies have uncovered a novel 
biochemical insight into the importance of prelamin A farnesylation. We show that protein 
farnesylation is important for efficient prelamin A processing by ZMPSTE24. The absence 
of farnesyl lipid anchor on prelamin A caused markedly reduced binding of a prelamin A 
peptide to ZMPSTE24 as well as reduced proteolysis. The fact that the absence of 
farnesylation retards but does not fully block ZMPSTE24-mediated prelamin A proteolysis 
probably explains a longstanding mystery in prelamin A processing. For years, it has been 
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unclear why high doses of potent protein farnesyltransferase inhibitors (FTIs) were 
incapable of fully inhibiting the biogenesis of mature lamin A from prelamin A34. Similarly, 
it was unexpected that a knockout of protein farnesyltransferase (or a knockout of both 
protein farnesyltransferase and geranylgeranyltransferase-I) in the liver did not completely 
abolish lamin A biogenesis from prelamin A35. Our current studies provide a plausible 
explanation—that ZMPSTE24-mediated prelamin A cleavage persists, albeit at a lower 
level, when prelamin A farnesylation is absent.
Having established conditions to monitor ZMPSTE24-mediated prelamin A processing, we 
examined the effects of HIV protease inhibitors on this process. We documented, for the first 
time, direct binding of HIV-PIs (lopinavir, ritonavir, amprenavir) to ZMPSTE24 and showed 
that each of those drugs blocked prelamin A proteolysis. We also showed that binding of 
these drugs confers stability upon ZMPSTE24 as evidenced by resistance to unfolding. 
Interestingly, darunavir did not bind to ZMPSTE24, or interfere with proteolysis. Our KD 
values are of the same order as previously reported IC50 values for lopinavir and ritonavir17, 
and our Western Blot studies on a human fibroblast cell line support the inhibition of 
prelamin A processing by lopinavir. Of note, our findings are also consistent with earlier 
studies showing that lopinavir is much more potent than darunavir in causing an 
accumulation of farnesyl–prelamin A in cultured fibroblasts17.
In our studies, we tested HIV protease inhibitor drugs over a range of concentrations from 4 
μM to 20 μM, which is similar to the therapeutic concentrations of the drugs36. Our 
biochemical findings are therefore consistent with the ability of similar concentrations of 
HIV-PIs to inhibit prelamin A processing in cultured cells as shown here and reported 
previously16,17. However, we would point out that HIV-PIs are highly protein-bound in 
plasma; thus, it is possible that the concentration of unbound (bioavailable) drug in the cells 
of HIV patients may be 30–100 fold lower37,38 than the 4 - 20 μM concentration used in our 
experiments. It would be highly desirable to define the effective concentration of drug in the 
nuclear membranes where ZMPSTE24 resides. ZMPSTE24 protein concentrations are also 
extremely relevant to the ability of HIV-PIs to block prelamin A processing16,17, and for that 
reason it would also be desirable to know the exact concentration of ZMPSTE24 protein in 
different tissues. At this point, there is conflicting information on the impact of HIV-PIs on 
prelamin A processing in vivo. Western blot studies show an accumulation of prelamin A in 
adipose tissue of HIV patients treated with an HIV-PI39, suggesting that HIV-PIs do inhibit 
ZMPSTE24 processing, but a more recent study did not find a significant effect of HIV-PIs 
on prelamin A processing in peripheral blood mononuclear cells20. We would argue that the 
biochemical findings in the current studies—that HIV-PIs bind directly to ZMPSTE24 and 
block proteolysis, provide an impetus to pursue additional studies to define the impact of the 
drugs on prelamin A processing in different tissues in vivo.
In conclusion, the mass spectrometry approaches that we applied in this study extend earlier 
studies of metal binding and drugs to soluble protein targets40–44 and provide direct 
evidence for the binding of HIV protease inhibitors to the membrane protein ZMPSTE24, 
with and without zinc binding, and in the presence of detergent and lipid adducts. This is not 
only the first direct evidence of drug binding to ZMPSTE24 but our results are corroborated 
by the resistance to unfolding conferred by these binding events. Our findings are also 
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important because it was intuitively surprising that these drugs, which were designed as 
aspartyl protease inhibitors, would bind to a zinc metalloprotease. We strongly suspect that 
these off-target binding events are common with frequently used pharmaceutical agents. We 
propose that the methodologies applied here will therefore be widely employed for probing 
these unwanted associations in other membrane proteins where the potential for off-target 
hydrophobic interactions is predicted to be high45.
Methods
Protein purification
ZMPSTE24 was overexpressed and purified as described by Quigley et al6. Briefly, full-
length ZMPSTE24 was expressed in Sf9 cells with an pFB-CT10HF-LIC vector containing 
a ZMPSTE24 open reading frame with a C-terminal tobacco etch virus (TEV) cleavage site, 
a 10× His tag, and a FLAG tag. The final protein was purified in OGNG detergent 
supplemented with 0.018% CHS.
Peptides
Synthetic peptides corresponding to the C-terminal sequences from of prelamin A 
(consisting of 26 or 14 amino acids) were synthesised by a commercial supplier (Peptide 
Protein Research Ltd). The C-terminal cysteine of the 26- mer peptide was farnesylated. A 
stock 20 mM solution of peptides in DMSO was prepared and diluted to 100 μM in a 200 
mM ammonium acetate buffer supplemented with 0.16% OGNG.
Human immunodeficiency virus protease inhibitors (HIV-PIs)
Lopinavir, ritonavir, amprenavir, and darunavir were purchased Sigma or Cambridge 
Biosciences in powder form. The drugs were solubilised in DMSO at a stock concertation of 
5 mM concentration and then further diluted to 100 μM in 200 mM ammonium acetate 
supplemented with 0.5% C8E4.
Mass spectrometry
QExactive—High-resolution mass spectrometry was performed using a modified 
QExactive hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany) optimised for transmission of high m/z ions (Heck Nat Methods) and 
analysis of membrane proteins24. Modifications included a lower frequency RF applied to 
the quadrupole, higher pressures in the HCD cell, and modified electronics for extended 
frequency range detection on the Orbitrap. Typically the following instrument conditions 
were applied: The capillary voltage was set at 1.2 kV, and the ion transfer capillary was set 
to 30 °C in order to maintain ‘soft’ evaporation conditions. The S-lens RF potential was set 
to 100 V for better transmission of protein-detergent micelles. The quadrupole was set to 
from 2,000 to 10,000 m/z range.
For OGNG solubilised ZMPSTE24 protein complexes, collisional activation was applied by 
adjusting the voltage applied in the HCD cell to 100 V. For C8E4 solubilised ZMPSTE24–
drug binding experiments, no activation was applied in the HCD cell in order to preserve 
drug binding. Argon pressure in the HCD cell was set at 1.29 × 10−9 mbar. The C-trap 
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entrance lens was set to 6.0 V. The automatic gain control was set to 1 × 106 with a 
maximum inject time of 100 ms. Scans were collected from 2,000 to 8,000 m/z and from 
500 to 800 m/z for protein complexes and drug molecules, respectively. For spectra recorded 
for drug molecules at low mass-to-charge ratios, the pressure in the HCD cell was decreased. 
The resolution of the instrument was set to 17,500 at m/z=200 (a transient time of 64 ms) 
with 1 microscan or 10 microscans summed into a single scan to increase signal-to-noise 
ratios. The noise level parameter was set to a default value 4.64. Calibration of the 
instrument was performed with cesium-iodide clusters up to 11,340 m/z.
QToF and Synapt G1—Solutions of ZMPSTE24 and various peptides were introduced 
into a modified QToF mass spectrometer using gold-coated glass needles, and spectra were 
recorded under the following conditions: capillary, cone, and collision cell voltages of 1.4 
kV, 50 V, and 150 V, respectively. The backing pressure was set to 4.9mBar. Drift time 
measurements of C8E4-solubilised ZMPSTE24 with or without drugs were performed on a 
Synapt G1 mass spectrometer under the following conditions: capillary, cone and transfer 
voltages of 1.4 kV, 10 V, and 10 V, respectively. The flow rate of Argon was set at 8 ml/min 
in the collision cell and nitrogen gas was admitted at a flow rate of 22 ml/min into the ion-
mobility cell, producing pressures of 7.2–7.3 × 10−2 mbar and 0.578 mbar, respectively. The 
backing pressure was set at 4.39 mbar.
Peptide binding experiments—Purified ZMPSTE24 was buffer exchanged to 200 mM 
ammonium acetate supplemented with 0.16% OGNG and 0.018% CHS using micro biospin 
columns (BioRad). Peptide solutions were added to buffer exchanged protein solutions to 
yield a final peptide concentration of 15 μM.
Drug binding experiments—ZMPSTE24 was buffer exchanged into 200 mM 
ammonium acetate supplemented with 0.5% C8E4 detergent. The stock solution of HIV-PI 
drugs were added to buffer exchanged ZMPSTE24 protein either separately, at 
concentrations from 2 to 18 μM, or in a 1:1:1 mixture of lopinavir, ritonavir and darunavir 
prepared by mixing equimolar concentrations to yield a final concentration of 7 μM for each 
drug.
Western blots
Cell extracts from a human fibroblast cell line that had been exposed for three days to a 
protein farnesyltransferase inhibitor (ABT-100, 0.5 μM) or lopinavir (20 μM) for 3 days 
were size-fractionated on 4–12% polyacrylamide-SDS gels. The size-fractionated proteins 
were then transferred to sheets of nitrocellulose membrane for western blotting. The blots 
were incubated with a goat IgG against human lamin A/C (Santa Cruz) or a monoclonal 
antibody (7G11) against the C terminus of prelamin A. Binding of the primary antibodies 
was detected with IRDye-conjugated secondary antibodies, followed by scanning of the 
blots with an Odyssey Infrared Imaging System (Li-Cor Biosciences).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mass spectrum of ZMPSTE24 reveals zinc binding. (A) High-resolution Orbitrap QExactive 
mass spectrum of ZMPSTE24 released from a detergent (octyl glucose neopentyl glycol, 
OGNG) micelle. Adduct peaks at higher m/z are due to binding of lipids (POPG and 
cholesterol hemisuccinate) that co-purify with the protein. Inset: holo and apo-metallo 
ZMPSTE24 can be resolved (masses of 55579 Da and 55517 Da, respectively), confirming 
that Zn2+ is bound to the majority of the protein population.
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Figure 2. 
Mass spectra of ZMPSTE24 allow the cleavage of the prelamin peptide to be monitred in 
real-time. ZMPSTE24 was preprared in OGNG micelles and incubated with with an 
equimolar concentration of the peptide the 26-mer prelamin A peptide. Mass spectra were 
recorded on a Q-Tof mass spectrometer at different time intervals as indicated. Apo protein 
charge states are labelled (brown triangles). Binding of the full-length 26-mer prelamin A 
peptide is observed within 2 min (blue peaks). The corresponding 15-mer peptide cleavage 
product is formed with time (green peaks). The majority of the peptide was cleaved within 
~12 min, and the cleaved peptide product remains associated with ZMPSTE24. The 
schematic for ZMPSTE24 depicts the full-length 26-mer prelamin A peptide and its farnesyl 
lipid tail (red). Right hand panels show the presence of 26-mer peptide and the cleavage 
product (1016 for the triply charged ion), indicating that the majority of the substrate peptide 
was hydrolysed within ~12 min to form the doubly charged product ion at 903 m/z.
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Figure 3. 
Mass spectra recorded after competitive binding of HIV protease inhibitor drugs to 
ZMPSTE24. An Orbitrap mass spectrum shows the interaction between ZMPSTE24 and 
1:1:1 solition of lopinavir, ritonavir, and darunavir (main panel). Left inset: expansion of the 
low m/z region of the spectrum confirms the presence of all three inhibitors in solution. 
Right inset: expansion of the mass spectrum from m/z 5020 – 5135 reveals binding of CHS, 
OGNG, lopinavir, and ritonavir to the 11+ charge state of ZMPSTE24. No peak was 
observed for binding of darunavir under these competitive binding conditions. Charge state 
series are labelled: yellow hexagon, zinc-bound ZMPSTE24; dark blue circle, 
ZMPSTE24·CHS; green circle, ZMPSTE24·OGNG; black circle, ZMPSTE24·lopinavir; red 
circle, ZMPSTE24·ritonavir.
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Figure 4. 
Collision-induced unfolding reveals differences in the unfolding trajectories of free 
ZMPSTE24 compared with its drug-bound states. (A) Mass spectrum and arrival times of 
ZMPSTE24 acquired under collisional activation (80 V) (upper panel) in the presence of 
ritonavir in C8E4. The arrival time distribution of the 11+ charge state is consistent with 
partial unfolding of the enzyme, whereas charge states 10+ and 9+ remain compact, 
consistent with native-like structure in the gas phase. Peaks assigned to binding of the drug 
are labelled with black circles. The 11+ charge states of apo and the ZMPSTE24 ritonavir 
complex, selected for collision induced unfolding measurements, are shown in the ion 
mobility data (white circle). Native and intermediate states are apparent at this voltage (80 
V). (B) Comparison of the collision-induced unfolding from 70 V to 110 V of the 11+ 
charge state of Zn2+-bound ZMPSTE24 with unfolding in the presence of ritonavir or 
lopinavir. The transition from compact folded state to the first intermediate state is 
highlighted (white arrows). This transition occurs at a higher voltage for lopinavir-bound 
ZMPSTE24 than for the ritonavir-bound ZMPSTE24.
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